BAYER AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.41 EUR | +1.93% |
|
+4.50% | -18.20% |
| 03:20pm | Dpa-AFX Overview: COMPANIES from 26.04.2024 - 15:15 | DP |
| 12:14pm | Bayer: CEO's positive AGM speech welcomed | CF |
| Sales 2024 * | 47.11B 50.48B | Sales 2025 * | 47.96B 51.39B | Capitalization | 26.42B 28.31B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.08B 2.23B | Net income 2025 * | 3.17B 3.39B | EV / Sales 2024 * | 1.26 x |
| Net Debt 2024 * | 33.11B 35.47B | Net Debt 2025 * | 29.67B 31.79B | EV / Sales 2025 * | 1.17 x |
| P/E ratio 2024 * |
12.3
x | P/E ratio 2025 * |
8.27
x | Employees | 96,931 |
| Yield 2024 * |
0.41% | Yield 2025 * |
0.86% | Free-Float | 99.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bayer AG
More press releases
| 1 day | +2.16% | ||
| 1 week | +4.39% | ||
| Current month | -3.34% | ||
| 1 month | +0.60% | ||
| 3 months | -14.96% | ||
| 6 months | -32.58% | ||
| Current year | -18.29% |
1 week
26.72
27.70
1 month
25.6128.94
Current year
24.9636.09
1 year
24.9660.31
3 years
24.9667.99
5 years
24.9678.34
10 years
24.96146.45
| Managers | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 57 | 23-03-31 |
| Director of Finance/CFO | 54 | 18-04-25 | |
Bijoy Sagar
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Colleen Goggins
BRD | Director/Board Member | 68 | 17-03-31 |
| Director/Board Member | 68 | 17-03-31 | |
Alberto Weisser
BRD | Director/Board Member | 67 | 21-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.77% | 70 M€ | -.--% | - | |
| 5.71% | 2 M€ | +13.56% | - | |
| 4.28% | 962 M€ | -.--% | - | |
| 4.10% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 27.51 | +2.29% | 2 772 579 |
| 24-04-25 | 26.9 | -0.28% | 3,533,816 |
| 24-04-24 | 26.97 | -1.37% | 2,710,724 |
| 24-04-23 | 27.34 | +0.11% | 3,055,329 |
| 24-04-22 | 27.32 | +3.76% | 4,999,901 |
Delayed Quote Xetra, April 26, 2024 at 09:28 am EDT
More quotes
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows:
- agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.;
- pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.;
- OTC products and nutritional supplements (12.7%);
- other (0.5%).
Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).
Sector
Pharmaceuticals
Calendar
04:00am
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
26.9
EUR
Average target price
36.9
EUR
Spread / Average Target
+37.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.29% | 28.3B | |
| +24.35% | 653B | |
| +25.81% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +12.85% | 233B | |
| +5.07% | 201B | |
| -9.86% | 193B | |
| -6.47% | 144B |
- Stock Market
- Equities
- BAYN Stock
